Orbimed Advisors LLC lessened its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 0.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,062,900 shares of the biopharmaceutical company’s stock after selling 44,300 shares during the period. Orbimed Advisors LLC owned about 9.54% of Achillion Pharmaceuticals worth $58,652,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ACHN. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 800 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 4,144 shares during the period. Legal & General Group Plc boosted its holdings in shares of Achillion Pharmaceuticals by 53.8% during the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 15,000 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Achillion Pharmaceuticals by 13.7% during the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 6,730 shares during the period. Finally, Bank of Montreal Can boosted its holdings in shares of Achillion Pharmaceuticals by 6.4% during the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 3,410 shares during the period. 76.93% of the stock is owned by institutional investors.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.24% of the stock is owned by insiders.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $2.90 on Friday. Achillion Pharmaceuticals, Inc. has a 12 month low of $2.88 and a 12 month high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. During the same quarter last year, the firm posted ($0.15) earnings per share. sell-side analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

Several brokerages recently commented on ACHN. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Monday, November 6th. ValuEngine downgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, September 11th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $4.00 target price (down previously from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $5.29.

TRADEMARK VIOLATION WARNING: “Orbimed Advisors LLC Has $58.65 Million Stake in Achillion Pharmaceuticals, Inc. (ACHN)” was reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/10/orbimed-advisors-llc-has-58-65-million-stake-in-achillion-pharmaceuticals-inc-achn.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.